{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T07:35:23Z","timestamp":1791099323137,"version":"4.1.0"},"reference-count":34,"publisher":"Manuscript Technomedia LLP","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Young Pharmacists"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.4103\/0975-1483.104367","type":"journal-article","created":{"date-parts":[[2012,12,5]],"date-time":"2012-12-05T13:55:40Z","timestamp":1354715740000},"page":"235-244","source":"Crossref","is-referenced-by-count":13,"title":["Antidepressant Potential of 5-HT3 Receptor Antagonist, N-n- propyl-3-ethoxyquinoxaline-2-carboxamide (6n)"],"prefix":"10.5530","volume":"4","author":[{"given":"R.","family":"Mahesh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Devadoss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.K.","family":"Jindal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.K.","family":"Gautam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.K.","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3478","reference":[{"key":"10.4103\/0975-1483.104367_bb0005","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/87865","article-title":"The cellular neurobiology of depression","volume":"7","author":"Manji","year":"2001","journal-title":"Nat Med"},{"key":"10.4103\/0975-1483.104367_bb0010","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0896-6273(02)00653-0","article-title":"Neurobiologyof depression","volume":"34","author":"Nestler","year":"2002","journal-title":"Neuron"},{"key":"10.4103\/0975-1483.104367_bb0015","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/01.psy.0000163456.22154.d2","article-title":"Hypercortisolemia and depression","volume":"67","author":"Gillespie","year":"2005","journal-title":"Psychosom Med"},{"key":"10.4103\/0975-1483.104367_bb0020","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1176\/appi.ajp.161.2.195","article-title":"Psychobiological mechanisms of resilience and vulnerability: Implications for successful adaptation to extreme stress","volume":"161","author":"Charne","year":"2004","journal-title":"Am J Psychiatry"},{"key":"10.4103\/0975-1483.104367_bb0025","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1080\/03009740410006961","article-title":"Spectrum of use and tolerability of 5-HT3 receptor Antagonists","volume":"119","author":"Haus","year":"2004","journal-title":"Scand J Rheumatol"},{"key":"10.4103\/0975-1483.104367_bb0030","first-page":"83","article-title":"Cancer chemotherapyinduced nausea and vomiting: Role of mediators, development of drugs and treatment methods","volume":"60","author":"Mahesh","year":"2005","journal-title":"Pharmazie"},{"key":"10.4103\/0975-1483.104367_bb0035","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1111\/j.1471-4159.1989.tb09244.x","article-title":"Identification and characterisation of 5-hydroxytryptamine 3 recognition sites in human brain tissue","volume":"53","author":"Barnes","year":"1989","journal-title":"J Neurochem"},{"key":"10.4103\/0975-1483.104367_bb0040","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/j.1471-4159.1993.tb03208.x","article-title":"Pharmacological and regional characterization of [3H] Y278584 binding sites in human brain","volume":"60","author":"Abi-Dargham","year":"1993","journal-title":"J Neurochem"},{"key":"10.4103\/0975-1483.104367_bb0045","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0014-2999(02)02960-6","article-title":"Targeted gene deletion of the 5- HT3A receptor subunitproduces an anxiolytic phenotype in mice","volume":"461","author":"Kelley","year":"2003","journal-title":"Eur J Pharmacol"},{"key":"10.4103\/0975-1483.104367_bb0050","first-page":"55","article-title":"Oral treatment of fibromyalgia with tropisetron given over 28 days: Influence on functional and vegetative symptoms, psychometric parameters and pain","volume":"113","author":"Haus","year":"2000","journal-title":"Scand J Rheumatol Suppl"},{"key":"10.4103\/0975-1483.104367_bb0055","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jad.2005.12.047","article-title":"Evidence for a vagal pathophysiology for bulimia nervosa and the accompanying depressive symptoms","volume":"92","author":"Fans","year":"2006","journal-title":"J Affect Disord"},{"key":"10.4103\/0975-1483.104367_bb0060","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1177\/0269881109348161","article-title":"The auspicious role of the 5-HT3 receptor in depression: A probable neuronal target","volume":"24","author":"Rajkumar","year":"2010","journal-title":"J Psychopharmacol"},{"key":"10.4103\/0975-1483.104367_bb0065","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1021\/jm00168a011","article-title":"Conformation-activity relationship study of 5-HT3 receptor antagonists and a definition of a model for this receptor","volume":"33","author":"Hibert","year":"1990","journal-title":"J Med Chem"},{"key":"10.4103\/0975-1483.104367_bb0070","doi-asserted-by":"crossref","first-page":"5179","DOI":"10.1016\/j.bmcl.2004.07.060","article-title":"Microwave assisted synthesis of 2-(4- substituted piperazin-l-yl)-l, 8- naphthyridine-3-carbonitrile as a new class of Serotonin 5-HT3 receptor antagonists","volume":"14","author":"Mahesh","year":"2004","journal-title":"Bioorg Med Chem Lett"},{"key":"10.4103\/0975-1483.104367_bb0075","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1472-8206.1990.tb01016.x","article-title":"Is it possible to predict the activity of a new antidepressant in animals with simple psychopharmacological tests?","volume":"4","author":"Bourin","year":"1990","journal-title":"Fundam Clin Pharmacol"},{"key":"10.4103\/0975-1483.104367_bb0080","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/00008877-199711000-00010","article-title":"The forced swimming test as a model for core and component behavioral effects of antidepressant drugs","volume":"8","author":"Lucki","year":"1997","journal-title":"Behav Pharmacol"},{"key":"10.4103\/0975-1483.104367_bb0085","first-page":"327","article-title":"Behavioral despair in mice: A primary Screening test for antidepressants","volume":"229","author":"Porsolt","year":"1977","journal-title":"Arch Int Pharmacodyn Ther"},{"key":"10.4103\/0975-1483.104367_bb0090","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/BF00428203","article-title":"The tail suspension test: A new method for Screening antidepressant drugs","volume":"85","author":"Steru","year":"1985","journal-title":"Psychopharmacology (Berl)"},{"key":"10.4103\/0975-1483.104367_bb0095","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/BF00181261","article-title":"The tail suspension test: Ethical considerations","volume":"90","author":"Thierry","year":"1986","journal-title":"Psychopharmacology (Berl)"},{"key":"10.4103\/0975-1483.104367_bb0100","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S1734-1140(10)70263-2","article-title":"Effect of acute and chronic treatment with QCF-3 (4-benzylpiperazin-l-yl) (quinoxalin-2- yl) methanone, a novel 5- HT3reeptor antagonist, in animal models of depression","volume":"62","author":"Devadoss","year":"2010","journal-title":"Pharmacol Rep"},{"key":"10.4103\/0975-1483.104367_bb0105","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0163-7258(97)00004-1","article-title":"The olfactory bulbectomized rat as a model of depression: An an update","volume":"74","author":"Kelly","year":"1997","journal-title":"Pharmacol Ther"},{"key":"10.4103\/0975-1483.104367_bb0110","first-page":"46","article-title":"Antidepressant like effect of pimozide in acute and chronic animal models of depression. Ind","volume":"45","author":"Mahesh","year":"2011","journal-title":"J Pharm Educ Res"},{"key":"10.4103\/0975-1483.104367_bb0115","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1113\/jphysiol.1968.sp008392","article-title":"The origin of acetylcholme released from guinea-pig intestine and longitudinal muscle strips","volume":"194","author":"Paton","year":"1968","journal-title":"J Physiol"},{"key":"10.4103\/0975-1483.104367_bb0120","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/j.2042-7158.1978.tb13237.x","article-title":"How should values of pA2 and affinity constants for pharmacological competitive antagonists be estimated","volume":"30","author":"MacKay","year":"1978","journal-title":"J Pharm Pharmacol"},{"key":"10.4103\/0975-1483.104367_bb0125","first-page":"212","article-title":"Action de la cafeine sur la motilite spontanee de la souris","volume":"158","author":"Simon","year":"1965","journal-title":"Arch Int Pharmacodyn Ther"},{"key":"10.4103\/0975-1483.104367_bb0130","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/0278-5846(89)90061-4","article-title":"Effects of truodothyronine (T3) on the potentiation by antidepressants of L-5-hydroxytryptophan-induced head-twitches m mice","volume":"13","author":"Martin","year":"1989","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.4103\/0975-1483.104367_bb0135","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0166-4328(03)00034-2","article-title":"Effects in various mice strains in the tail suspension test","volume":"143","author":"Ripoll","year":"2003","journal-title":"Behav Brain Res"},{"key":"10.4103\/0975-1483.104367_bb0140","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.bbr.2005.06.015","article-title":"A proposal of decision tree to screen putative antidepressants using; forced swim and tail suspension tests","volume":"164","author":"Bourin","year":"2005","journal-title":"Behav Brain Res"},{"key":"10.4103\/0975-1483.104367_bb0145","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1476-5381.1973.tb08369.x","article-title":"The effects of. (\u2212)-delta9-tetrahydrocannabinol on reserpine- induced hypothermia in rats","volume":"49","author":"Englert","year":"1973","journal-title":"BrJ Pharmacol"},{"key":"10.4103\/0975-1483.104367_bb0150","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/BF02247730","article-title":"Concentration of ondansetron in cerebrospinal fluid following oral dosing in volunteers","volume":"109","author":"Simpson","year":"1992","journal-title":"Psychopharmacology (Berl)"},{"key":"10.4103\/0975-1483.104367_bb0155","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1080\/030097400446625","article-title":"Preclinical and clinical pharmacology of the 5-HT3 receptor antagonists","volume":"113","author":"Wolf","year":"2000","journal-title":"Scand J Rheumatol Suppl"},{"key":"10.4103\/0975-1483.104367_bb0160","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1021\/np50086a003","article-title":"A bioassay for Inhibition of Serotonin release from bovine platelets","volume":"55","author":"Maries","year":"1992","journal-title":"J Nat Prod"},{"key":"10.4103\/0975-1483.104367_bb0165","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1124\/mol.61.5.953","article-title":"Parthenolide, an Inhibitor of the nuclear factor-B pathway, ameliorates cardiovascular derangement and outcome in endotoxic shock in rodents","volume":"61","author":"Sheehan","year":"2002","journal-title":"Mol Pharmacol"},{"key":"10.4103\/0975-1483.104367_bb0170","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.bbr.2011.03.017","article-title":"Cognitive and locomotor\/exploratory behavior after chronic exercise in the olfactory bulbectomy model of depression","volume":"222","author":"Van Hoomissen","year":"2011","journal-title":"Behav Brain Res"}],"container-title":["Journal of Young Pharmacists"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T08:56:04Z","timestamp":1771577764000},"score":1,"resource":{"primary":{"URL":"https:\/\/jyoungpharm.org\/article\/4\/4\/235"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["S0975148312440067"],"URL":"https:\/\/doi.org\/10.4103\/0975-1483.104367","relation":{},"ISSN":["0975-1483"],"issn-type":[{"value":"0975-1483","type":"print"}],"subject":[],"published":{"date-parts":[[2012,10]]}}}